Orders from 465 AED Free delivery from 965 AED Ready for pickup dead drop: collect in 5 min

Substances · Cathinone derivatives

α-PVP

C15H21NO CAS 14530-33-7 Analytical reference material — not for human consumption
Preferred name
α-PVP
IUPAC name
1-phenyl-2-pyrrolidin-1-ylpentan-1-one
Parent CAS number (reference)
14530-33-7
Molecular formula
C15H21NO
Molecular weight
231.33 g/mol
InChIKey
YDIIDRWHPFMLGR-UHFFFAOYSA-N
PubChem
CID 11148955
Source
PubChem
Verified synonyms & catalog abbreviations
alpha-PVP a-PVP aPVP alpha-pyrrolidinopentiophenone O-2387

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

alpha-PVP (alpha-Pyrrolidinovalerophenone / alpha-Pyrrolidinopentiophenone)

Potent Stimulant (Ultra-High-Affinity NDRI) Substituted cathinone / Pyrrolidinophenone (desmethylpyrovalerone)
Verified PubChem & CAS Identity C15H21NO · CAS 14530-33-7 · CID 11148955
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 231.34 g/mol
Peer-Reviewed & Agency Citations 4 · verified sources

Receptor Telemetry & Mechanism of Action

DAT Dopaminergic Signaling Primary
NET Noradrenergic Signaling Active
SERT Serotonergic Signaling Variable

One of the most potent dopamine-norepinephrine reuptake inhibitors (NDRIs) characterized in vitro: high lipophilicity from the pyrrolidine ring drives rapid blood-brain barrier permeation, yielding DAT IC50 = 12.8–19.7 nM (Ki = 22.2 nM) and NET IC50 = 14.2–46 nM (Ki = 122 nM) with zero substrate release and negligible SERT inhibition (IC50 > 10,000–57,000 nM; DAT/SERT ratio > 781–2,900). Neurochemical and cardiovascular actions reflect primarily the (S)-enantiomer.

Biotransformation & Active Metabolites

Metabolized by hepatic CYP2B6, CYP2D6, CYP2C19, and CYP3A4 primarily to 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-ol (OH-alpha-PVP) and 2''-oxo-alpha-PVP lactam. Human elimination half-life is ~2.1 hours, with clinical BP/HR peaking at 40 minutes.

Temporal Pharmacokinetics

Fierce, razor-sharp catecholaminergic rush marked by intense psychomotor stimulation, hyper-vigilance, compulsive repeated exposure cravings, strong peripheral vasoconstriction, and rapid escalation into agitation and paranoia.

  1. Onset 2–20 minutes oral
  2. Peak Window 1–2.5 hours (clinical cardiovascular peak at 40–60 minutes)
  3. Total Window 2–6 hours (clinical subjective duration 3–5 hours)
  4. Residual / Half-Life 4–12 hours of insomnia, adrenergic tension, anxiety, and crash; human elimination half-life is ~2.1 hours.

Extremely steep dose-response curve: threshold starts at 1 mg, common oral range is 10–25 mg, and exceeding 40–50 mg (or binge repeated exposure) carries a documented high rate of excited delirium, paranoid psychosis, hyperthermia (40–41 °C), rhabdomyolysis, acute renal failure, and cardiac arrest.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
1 mg
Cognitive & Sensory

Subtle increase in alertness, vigilance, and wakefulness.

Somatic & Autonomic

Faint adrenergic crispness.

Light
5–10 mg
Cognitive & Sensory

Brisk mental energy, task focus, talkativeness, and modest mood lift.

Somatic & Autonomic

Noticeable elevation in heart rate and blood pressure, dry mouth, and appetite suppression.

Common Reference
10–25 mg
Cognitive & Sensory

Intense psychomotor rush, ego inflation, heightened libido, rapid thought acceleration, and strong urge to redose.

Somatic & Autonomic

Marked tachycardia, systolic/diastolic hypertension peaking around 40–60 minutes, sweating, jaw clenching, and vasoconstriction.

Strong
25–40 mg (CAHMA strong: 25–50 mg)
Cognitive & Sensory

Forced, jittery stimulation, restless tremors, hyper-vigilant anxiety, thought loops, and paranoid suspicion.

Somatic & Autonomic

Severe peripheral vasoconstriction, muscle spasms, restless legs, bruxism, chest tightness, and hyperthermia.

Heavy / Toxic Zone
40–50+ mg
Cognitive & Sensory

Acute paranoid psychosis, terrifying hallucinations, violent agitation, and excited delirium.

Somatic & Autonomic

Life-threatening hyperthermia (40–41 °C), rhabdomyolysis, acute kidney failure, myoclonus, seizures, cerebral hemorrhage, and myocardial infarction.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

MAOIs (phenelzine, tranylcypromine, moclobemide, harmala alkaloids)

12.8 nM DAT and 14.2 nM NET blockade combined with MAO inhibition causes immediate, fatal hypertensive crisis, stroke, and hyperpyrexia.

All other stimulants and 25x-NBOMe / 25x-NBOH (Cocaine, alpha-PHP, alpha-PiHP, MDPHP, NEP, Hexen, MDMA, Amphetamines)

Extreme synergistic tachycardia, vasospasm, hyperthermia, rhabdomyolysis, seizures, and cardiac arrest.

Tramadol and Opioids

Tramadol triggers convulsions; opioids risk fatal respiratory depression once alpha-PVP's ~2.1-hour half-life clears.

Elevated Hazard — Avoid

Alcohol and GHB/GBL

Worsens dehydration, hyperthermia, and rhabdomyolysis while masking lethal depressant intoxication.

Dissociatives (PCP/PCE analogues) and Psychedelics

High probability of triggering acute psychotic delirium, extreme panic, and uncontrolled behavioral crises.

Caution / Receptor Attenuation

CYP2D6 / CYP3A4 / CYP2C19 / CYP2B6 inhibitors

Slows hepatic oxidation of alpha-PVP, raising blood levels toward the >100 ug/L clinical intoxication and >300 ug/L overdose range.

Cannabis

Strongly provokes paranoid delusions and severe tachycardia.

Structural Isomer & Sibling Comparison

alpha-PVP is the sharpest, most noradrenergically intense benchmark of the pyrovalerone family (NET IC50 14.2 nM vs. 41.4 nM for alpha-PiHP and 60–935 nM for MDPHP). Compared to 6-carbon homologue alpha-PHP, alpha-PVP has a slightly shorter total window (2–6 h vs. 2–8 h) and shorter after-effects (4–12 h vs. up to 48 h), while hitting with a harsher cold adrenergic edge. Compared to NEP and Hexen, alpha-PVP is ~2.4–10x more potent at DAT/NET.

Physicochemical Stability & Storage

Form: White or off-white odorless crystalline powder or crystals as the hydrochloride salt (mp ~161.3 °C; freebase mp ~173 °C). · HCl salt is soluble in ethanol (~20 mg/mL), PBS (pH 7.2, ~10 mg/mL), DMSO (~10 mg/mL), and DMF (~3 mg/mL).

Store dry and tightly sealed away from light and heat.

Cross-Tolerance & Dependence Profile

Very high addiction liability due to rapid blood-brain barrier entry and ~2.1-hour half-life. Cross-tolerant with alpha-PHP, alpha-PiHP, MDPHP, NEP, and cocaine (3–7 days to halve, 1–2 weeks to baseline).

Comprehensive Analytical & Toxicological Monograph

alpha-PVP (alpha-pyrrolidinovalerophenone / O-2387; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one; freebase CAS 14530-33-7, hydrochloride CAS 5485-65-4, PubChem CID 11148955) is the prototypical five-carbon pyrrolidinophenone cathinone queued in weekly synthesis slot #13 as pure analytical crystals or crystalline powder (C15H21NO, 231.34 g/mol). Its lipophilic pyrrolidine ring enables rapid blood-brain barrier permeation and ultra-potent, pure catecholamine uptake blockade (DAT IC50 = 12.8–19.7 nM, NET IC50 = 14.2–46 nM) with negligible serotonin transporter activity (SERT IC50 > 10,000 nM). Controlled human pharmacodynamic studies demonstrate acute increases in blood pressure and heart rate peaking at 40–60 minutes, with primary subjective effects resolving across 3–5 hours alongside an elimination half-life of ~2.1 hours via hepatic CYP2B6/2D6/2C19/3A4 metabolism. Because alpha-PVP has an exceptionally steep dose-response curve, volumetric liquid measurement or laboratory-grade milligram weighing is indispensable: oral threshold activity begins at 1 mg, light stimulation spans 5–10 mg, common stimulation sits at 10–25 mg, strong forced stimulation with vasoconstriction and hyper-vigilance occurs at 25–40 mg, and amounts above 40–50 mg (or binge repeated exposure) carry documented risks of paranoid psychosis, excited delirium, hyperthermia (40–41 °C), rhabdomyolysis, acute renal failure, cerebral hemorrhage, and myocardial infarction. Compared to alpha-PHP and alpha-PiHP, alpha-PVP delivers the strongest noradrenergic rush (NET IC50 14.2 nM) with a shorter residual tail than alpha-PHP, while exceeding NEP and Hexen in transporter potency several-fold. Never combine alpha-PVP with MAOIs, any other stimulant, tramadol, opioids, dissociatives, or 25x-NBOMe.

Chemical Architecture & Structural Profile

α-PVP (1-phenyl-2-pyrrolidin-1-ylpentan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C15H21NO and a molar mass of 231.33 g/mol. The parent molecule is indexed under CAS registry number 14530-33-7 and in the NCBI PubChem database as CID 11148955 (Standard InChIKey: YDIIDRWHPFMLGR-UHFFFAOYSA-N). This molecule shares its empirical formula (C15H21NO) with positional or structural isomers; unambiguous analytical identification requires matching the full IUPAC structure, CAS number (14530-33-7), and spectroscopic profile.

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), α-PVP is indexed within the Cathinone, Substituted cathinones, Substituted pyrrolidines structural group. Toxicological notes (PsychonautWiki): exact toxic threshold is unknown. Dependence liability (PsychonautWiki): highly addictive with a high potential for abuse. Documented cross-tolerance class: dopamine, stimulant. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Unsafe combinations (elevated hazard)

Uncertain combinations (caution advised)